Lamitrin S

Leaflet accompanying the packaging: information for the user

Lamitrin S, 2 mg, chewable/disintegrating tablets / for oral suspension

Lamitrin S, 5 mg, chewable/disintegrating tablets / for oral suspension

Lamitrin S, 25 mg, chewable/disintegrating tablets / for oral suspension

Lamitrin S, 50 mg, chewable/disintegrating tablets / for oral suspension

Lamitrin S, 100 mg, chewable/disintegrating tablets / for oral suspension

Lamitrin S, 200 mg, chewable/disintegrating tablets / for oral suspension

Lamotrigine

You should carefully read the contents of this leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult your doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

1 What is Lamitrin S and what is it used for

2 Important information before taking Lamitrin S

3 How to take Lamitrin S

4 Possible side effects

5 How to store Lamitrin S

6 Contents of the pack and other information

1. What is Lamitrin S and what is it used for

Lamitrin S belongs to a group of medicines called antiepileptic drugs. It is used to treat two diseases – epilepsy and bipolar affective disorders.
The action of Lamitrin S in the treatment of epilepsyinvolves blocking impulses in the brain that cause epileptic seizures.

• In adults and children over 13 years of age, Lamitrin S may be used alone or in combination with other medicines to treat epilepsy. Lamitrin S may also be used in combination with other medicines to treat epileptic seizures associated with a condition called Lennox-Gastaut syndrome.
• In children between 2 and 12 years of age, Lamitrin S may be used in combination with other medicines to treat these diseases. It may be used as the only medicine to treat a type of epilepsy called typical absence seizures.

Lamitrin S is also used to treat bipolar affective disorders.

In patients with bipolar affective disorders (sometimes called manic-depressive psychosis), there are extreme mood swings with episodes of mania (excitement or euphoria) alternating with episodes of depression (deep sadness or despair). In adults over 18 years of age, Lamitrin S can be used alone or in combination with other medicines to prevent depressive episodes in bipolar affective disorders. The mechanism by which Lamitrin S works in the brain is not yet fully understood.

2. Important information before taking Lamitrin S

When not to take Lamitrin S

• If the patient has been diagnosed with an allergy(hypersensitivity) to lamotrigine or any of the other ingredients of this medicine (listed in section 6). In this case: The doctor should be informedand Lamitrin S should not be taken.

Warnings and precautions

When to exercise special caution when taking Lamitrin S

Before starting to take Lamitrin S, the doctor should be consulted if:

• The patient has any kidney disease;
• The patient has ever had a rashafter taking lamotrigine or other medicines used to treat bipolar affective disorders or epilepsy;
• The patient has ever had a rash or sunburnafter taking lamotrigine and being exposed to sunlight or artificial light (e.g. in a solarium). The doctor will verify the treatment used by the patient and may advise avoiding sunlight or using sun protection (e.g. using a sunscreen or wearing protective clothing);
• The patient has ever had meningitisafter taking lamotrigine (read the description of symptoms in section 4 of this leaflet: Rare side effects);
• The patient is taking a medicine containing lamotrigine;
• The patient has a condition called Brugada syndrome or other heart diseases.Brugada syndrome is a genetically determined heart condition characterized by disturbances in the electrical function of the heart. Abnormal ECG recordings are associated with arrhythmia (abnormal heart rhythm), which may be caused by taking lamotrigine.

In the event of any of these cases:
The doctor should be informed, who may recommend reducing the dose or deciding that Lamitrin S is not a suitable medicine for the patient.

Important information about life-threatening reactions

In a small number of patients taking Lamitrin S, an allergic reaction or potentially life-threatening skin reaction may occur, which may worsen if left untreated. Such reactions may occur more frequently during the first few months of taking Lamitrin S, especially when the patient has been given too high a dose, the dose has been increased too quickly, or the patient is taking Lamitrin S in combination with another medicine called valproate. Some of these reactions occur more frequently in children, so parents should pay particular attention to them.
These reactions include:

• skin rashes or redness, which can worsen to severe or sometimes life-threatening skin reactions, including a rash with ring-shaped lesions resembling a target ( erythema multiforme), widespread rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals ( Stevens-Johnson syndrome), widespread peeling of the skin (covering more than 30% of the body surface - toxic epidermal necrolysis), or a widespread rash accompanied by changes in the liver, blood, and other organs (drug reaction with eosinophilia and systemic symptoms, also known as DRESS syndrome).

Hemophagocytic lymphohistiocytosis (HLH)

Patients taking lamotrigine have reported cases of a rare but very severe reaction of the immune system.
If the patient experiences any of the following symptoms while taking lamotrigine: fever, rash, neurological symptoms (e.g. tremors or chills, confusion, brain function disorders), they should immediately contact their doctor or pharmacist.

Thoughts of self-harm or suicide

Antiepileptic medicines are used to treat various diseases, including epilepsy and bipolar affective disorders. In patients with bipolar affective disorders, thoughts of self-harm or suicide may sometimes occur. If the patient has bipolar affective disorders, such thoughts may occur more frequently:

• when starting treatment for the first time
• if the patient has had thoughts of self-harm or suicide before
• if the patient is under 25 years of age. If the patient experiences disturbing thoughts or feelings, or if they feel worse or experience new symptoms while taking Lamitrin S:

They should see their doctor as soon as possible

for help.

It may be helpful to inform a relative, caregiver, or friend that the patient may experience depression or significant mood changes and ask them to read this leaflet.

The patient may ask them to inform them if they notice that the patient is depressed or has disturbing changes in behavior.

In a small number of patients treated with antiepileptic medicines, such as Lamitrin S, thoughts of self-harm or suicide have also occurred. If the patient has ever had such thoughts, they should immediately contact their doctor.

Taking Lamitrin S for the treatment of epilepsy

Seizures in some types of epilepsy may sometimes worsen or occur more frequently while taking Lamitrin S. In some patients, severe seizures may occur, which can pose a serious threat to the patient's health. If the patient experiences more frequent or severe seizures while taking Lamitrin S:
they should see their doctor as soon as possible.

Lamitrin S should not be used to treat bipolar affective disorders in patients under 18 years of age

Medicines used to treat depression or other mental disorders increase the risk of suicidal thoughts or behaviors in children and adolescents under 18 years of age.

Lamitrin S and other medicines

The patient should tell their doctor or pharmacist about all medicines they are taking

currently or recently, as well as any medicines they plan to take, including herbal medicines or other medicines available without a prescription.
The doctor should be aware that the patient is taking other medicines used to treat epilepsy or mental disorders. This will allow the doctor to determine the appropriate dose of Lamitrin S. These medicines include:

• oxcarbazepine, felbamate, gabapentin, levetiracetam, pregabalin, topiramate, zonisamide, used to treat epilepsy
• olanzapineor aripiprazole, used to treat mental disorders
• bupropion, used to treat mental disordersor nicotine addiction
• paracetamol, used to treat pain or fever
  The doctor should be informedif the patient is taking any of these medicines.

Some medicines interact with Lamitrin S or increase the risk of side effects. These medicines include:

• valproate, used to treat epilepsy or mental disorders
• carbamazepine, used to treat epilepsy or mental disorders
• phenytoin, primidoneor phenobarbital, used to treat epilepsy
• risperidone, used to treat mental disorders
• rifampicin, which is an antibiotic
• medicines used to treat HIV infection(a combination of lopinavir with ritonavir or atazanavir with ritonavir)
• hormonal contraceptivessuch as birth control pills ( see below) The doctor should be informedif the patient is taking, has taken, or is about to take any of these medicines.

Hormonal contraceptives (such as birth control pills) may affect the action of Lamitrin S

The doctor may recommend using a specific type of hormonal contraceptive or another method of contraception, such as a condom, diaphragm, or intrauterine device. If the patient is using hormonal contraceptives, such as birth control pills, the doctor may recommend blood tests to check the level of Lamitrin S in the blood. If the patient is using or plans to use hormonal contraceptives:
they should discuss this with their doctorabout the appropriate method of contraception.
Lamitrin S may also affect the action of hormonal contraceptives, although it is unlikely to reduce their effectiveness. If the patient is using hormonal contraceptives and notices any changes in their menstrual cycle, such as bleeding or spotting:
they should inform their doctor. Such symptoms may indicate that Lamitrin S is affecting the action of the contraceptive.

Pregnancy and breastfeeding

If the patient is pregnant or thinks they may be pregnant, or if they plan to become pregnant, they should consult their doctor or pharmacist before taking this medicine.

• The patient should not stop taking the medicine without first consulting their doctor. This is especially important if the patient has epilepsy.
• Pregnancy may affect the effectiveness of Lamitrin S, so there may be a need for blood tests and adjustment of the dose of Lamitrin S.
• There may be a small increased risk of birth defects, including cleft lip and palate, if Lamitrin S is taken during the first three months of pregnancy.
• If the patient plans to become pregnant or is pregnant, their doctor may recommend taking folic acidin addition.

During breastfeeding or if the patient plans to breastfeed, they should consult their doctor or pharmacist before taking

this medicine. The active substance of Lamitrin S passes into breast milk and may affect the baby. The doctor will discuss the risks and benefits of breastfeeding while taking Lamitrin S, and if the patient decides to breastfeed, the doctor will periodically check the baby for excessive sleepiness, rash, or poor weight gain. If any of these symptoms are noticed in the baby, the doctor should be informed.

Driving and using machines

Lamitrin S may cause dizziness and double vision.

The patient should not drive or operate machinery unless they are sure that these symptoms do not occur

If the patient has epilepsy, they should discuss driving and operating machinery with their doctor

Lamitrin S chewable/disintegrating tablets / for oral suspension contain less than 1 mmol

(23 mg) of sodium per tablet, i.e. the medicine is considered sodium-free.

3. How to take Lamitrin S

This medicine should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.

What dose of Lamitrin S to take

Determining the appropriate dose of Lamitrin S for the patient may take time. The dose taken by the patient depends on:

• the patient's age
• whether the patient is taking Lamitrin S in combination with other medicines
• whether the patient has any kidney or liver disease.

The doctor will initially prescribe a small dose, which will then be gradually increased over several weeks until an effective dose is reached for the patient (called the effective dose). The patient should never take a higher dose of Lamitrin S than that recommended by their doctor.
Usually, the effective dose of Lamitrin S in adults and children over 13 years of age is between 100 mg and 400 mg per day.
In children between 2 and 12 years of age, the effective dose depends on the child's weight – usually between 1 mg and 15 mg per kilogram of body weight, up to a maximum maintenance dose of 200 mg per day.
Taking Lamitrin S is not recommended in children under 2 years of age.

Taking the dose of Lamitrin S

The dose of Lamitrin S should be taken once or twice a day, as directed by the doctor. Lamitrin S can be taken with or without food.

• The patient should always take the entire doseprescribed by the doctor. They should never take only part of a tablet.

The doctor may also recommend starting or stopping other medicines, depending on the indication and the patient's response to treatment.
The chewable/disintegrating tablets / for oral suspension of Lamitrin S can be swallowed whole with a small amount of water or chewed or taken in liquid form after mixing with water. The patient should never take only part of the suspension.

Removing a tablet from the blister pack

These tablets are provided in a special child-resistant packaging.

Each blister pack has a number on it. The tablets should be taken in sequence, following the numbering, starting from number 1.

• 1. Separating one tablet:to separate a blister pack with one tablet, tear the blister pack along the perforated lines.

• 2. Removing the outer layer:starting from the corner, peel off and remove the outer layer from the separated blister pack.

• 3. Removing the tablet:gently push one edge of the tablet through the foil.

Chewing the tablet:

Drinking a small amount of water at the same time can help dissolve the tablet in the mouth. Then, the patient should drink a little more water to make sure the entire dose has been swallowed.

To prepare an oral suspension:

• place the tablet in a glass and add enough water to cover the tablet;
• stir or wait until the tablet has completely dissolved;
• drink the prepared suspension in its entirety;
• add a small amount of water to the glass and drink it to ensure that the medicine has not been left in the glass.

Taking a higher dose of Lamitrin S than recommended

The patient should immediately contact their doctor or the nearest emergency department.
If possible, they should show the packaging of Lamitrin S.
Taking too high a dose of Lamitrin S may increase the risk of serious side effects, which can be fatal.
In a person who has taken too high a dose of Lamitrin S, the following symptoms may occur:

• rapid, involuntary eye movements ( nystagmus)
• uncoordinated movements, lack of coordination, inability to maintain balance ( ataxia)
• heart rhythm disturbances (detectable by ECG)
• loss of consciousness, seizures, or coma.

Missing a single dose of Lamitrin S

The patient should not take extra tablets to make up for the missed dose. They should take the next dose at the usual time.

If the patient misses several doses of Lamitrin S

The patient should consult their doctor about restarting

treatment with Lamitrin S. This is important for the patient.

The patient should not stop taking Lamitrin S unless their doctor advises them to do so

Lamitrin S must be taken for as long as the doctor recommends. The patient should not stop taking it unless their doctor advises them to do so.

Taking Lamitrin S for the treatment of epilepsy

To stop taking Lamitrin S, it is essential to gradually reduce the doseover about two weeks. If the patient suddenly stops taking Lamitrin S, their epilepsy symptoms may return or worsen.

Taking Lamitrin S for the treatment of bipolar affective disorders

It may take some time for Lamitrin S to start working, so it is unlikely that an improvement will occur immediately. When stopping treatment with Lamitrin S, there is no need to gradually reduce the dose. However, the patient should consult their doctor if they plan to stop taking Lamitrin S.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Life-threatening reactions: the patient should immediately contact their doctor.

In a small number of patients taking Lamitrin S, an allergic reaction or potentially life-threatening skin reaction may occur, which may worsen if left untreated.
Such reactions may occur more frequently during the first few months of taking Lamitrin S, especially when the patient has been given too high a dose, the dose has been increased too quickly, or the patient is taking Lamitrin S in combination with another medicine called valproate. Some of these reactions occur more frequently in children, so parents should pay particular attention to them.
These reactions include:

• skin rashes or redness, which can worsen to severe or sometimes life-threatening skin reactions, including a rash with ring-shaped lesions resembling a target ( erythema multiforme), widespread rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals ( Stevens-Johnson syndrome), widespread peeling of the skin (covering more than 30% of the body surface - toxic epidermal necrolysis), or a widespread rash accompanied by changes in the liver, blood, and other organs (drug reaction with eosinophilia and systemic symptoms, also known as DRESS syndrome).

Very common side effects

May occur in more than 1 in 10patients:

• headache
• skin rash.

Common side effects

May occur in up to 1 in 10patients:

• aggression or irritability
• drowsiness
• dizziness
• tremors
• difficulty sleeping ( insomnia)
• feeling of excitement
• diarrhea
• dry mouth
• nausea or vomiting
• feeling of tiredness
• back pain, joint pain, or pain in any other location.

Uncommon side effects

May occur in up to 1 in 100patients:

• uncoordinated movements and lack of coordination ( ataxia)
• double or blurred vision
• unusual hair loss ( alopecia)
• skin rash or sunburn after exposure to sunlight or artificial light (phototoxicity).

Rare side effects

May occur in up to 1 in 1,000patients:

• a skin reaction that causes red spots and patches on the skin, which can look like a target or "bull's eye" with a dark red center surrounded by lighter red rings ( erythema multiforme)
• a life-threatening skin reaction ( Stevens-Johnson syndrome: also see the information at the beginning of section 4).

Very rare side effects

May occur in up to 1 in 10,000patients:

• a life-threatening skin reaction ( toxic epidermal necrolysis: also see the information at the beginning of section 4)
• drug reaction with eosinophilia and systemic symptoms (DRESS) ( see section 4)
• high fever ( fever: also see the information at the beginning of section 4)
• swelling of the face, enlarged lymph nodes in the neck, armpits, and groin ( generalized lymphadenopathy: also see the information at the beginning of section 4)
• liver function changes, which have been detected in blood tests, or liver failure: also see the information at the beginning of section 4
• a severe blood clotting disorder that can cause unexpected bleeding or bruising ( disseminated intravascular coagulation: also see the information at the beginning of section 4)
• hemophagocytic lymphohistiocytosis (HLH) (see section 2. Important information before taking Lamitrin S)
• changes in blood test results, including a decrease in the number of red blood cells ( anemia), a decrease in the number of white blood cells ( leukopenia, neutropenia, agranulocytosis), a decrease in the number of platelets ( thrombocytopenia), a decrease in the number of all blood cells ( pancytopenia), and a bone marrow disorder called aplastic anemia
• hallucinations ( "seeing" or "hearing" things that are not real)
• disorientation
• feeling of instability or loss of balance while moving
• involuntary repetitive movements of the body and (or) sounds or words (tics), involuntary muscle contractions affecting the eyes, head, and trunk (choreoathetosis), or other unusual body movements, such as jerks, tremors, or stiffness
• increased frequency of seizures in patients with previously diagnosed epilepsy
• worsening of symptoms in patients with diagnosed Parkinson's disease
• a condition that may include back or joint pain, which may be accompanied by fever and (or) general malaise ( pseudolymphoma).

Other side effects

Other side effects have occurred in a small number of patients, but the frequency is unknown.

• Reports have been made of bone disorders, including osteopenia and osteoporosis (weakening of the bones) and fractures. If the patient is being treated with antiepileptic medicines for a long time, has previously had osteoporosis, or is taking steroids, they should discuss this with their doctor or pharmacist
• Kidney inflammation ( interstitial nephritis) or concurrent kidney and eye inflammation ( interstitial nephritis and uveitis)
• Nightmares
• Decreased immunity due to lower levels of antibodies in the blood, called immunoglobulins, which help protect the body against infections
• Red bumps or patches on the skin (pseudolymphoma).

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.

5. How to store Lamitrin S

The medicine should be stored in a place that is out of sight and reach of children.
The patient should not take this medicine after the expiry date stated on the blister pack, carton, or bottle. The expiry date refers to the last day of the month.
There are no special precautions for storing Lamitrin S.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What Lamitrin S chewable/disintegrating tablets / for oral suspension contain

The active substance is lamotrigine. Each chewable/disintegrating tablet / for oral suspension contains 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, or 200 mg of lamotrigine, respectively.
The other ingredients are calcium carbonate, hydroxypropylcellulose, low-substituted aluminum-magnesium silicate, sodium carboxymethylcellulose (type A), povidone K30, sodium saccharin, magnesium stearate, blackcurrant flavor.

What Lamitrin S chewable/disintegrating tablets / for oral suspension look like and what the pack contains:

Lamitrin S chewable/disintegrating tablets / for oral suspension (all strengths) are white to almost white and may be slightly speckled. They have a blackcurrant flavor. Not all pack sizes may be marketed.
Lamitrin S, 2 mg, chewable/disintegrating tablets / for oral suspension are round. They are marked with the inscription "LTG" above the inscription "2" on one side; on the other side, two intersecting ellipses are visible. Each bottle contains 30 tablets.
Lamitrin S, 5 mg, chewable/disintegrating tablets / for oral suspension are oval, biconvex. They are marked with the inscriptions "GS CL2" on one side and "5" on the other side. Each pack contains 10, 14, 28, 30, 42, 50, or 56 tablets in blisters or 14, 28, 30, 42, 56, or 60 tablets in a bottle.
Lamitrin S, 25 mg, chewable/disintegrating tablets / for oral suspension are multi-faceted, square with rounded corners. They are marked with the inscriptions "GSCL5" on one side and "25" on the other side. Each pack contains 10, 14, 21, 28, 30, 42, 50, 56, or 60 tablets in blisters.
Lamitrin S, 50 mg, chewable/disintegrating tablets / for oral suspension are multi-faceted, square with rounded corners. They are marked with the inscriptions "GSCX7" on one side and "50" on the other side. Each pack contains 10, 14, 28, 30, 42, 50, 56, 60, 90, 98, 100, 196, or 200 tablets in blisters.
Lamitrin S, 100 mg, chewable/disintegrating tablets / for oral suspension are multi-faceted, square with rounded corners. They are marked with the inscriptions "GSCL7" on one side and "100" on the other side. Each pack contains 10, 14, 28, 30, 42, 50, 56, 60, 90, 98, 100, 196, or 200 tablets in blisters.
Lamitrin S, 200 mg, chewable/disintegrating tablets / for oral suspension are multi-faceted, square with rounded corners. They are marked with the inscriptions "GSEC5" on one side and "200" on the other side. Each pack contains 10, 14, 28, 30, 42, 50, 56, 60, 90, 98, 100, 196, or 200 tablets in blisters.

Marketing authorization holder and manufacturer

Marketing authorization holder:
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
D24 YK11
Ireland
Manufacturer:
Delpharm Poznań Spółka Akcyjna
ul. Grunwaldzka 189
60-322 Poznań
Poland

This medicine is authorized in the Member States of the European Economic Area under the following names:

For more information, the patient should contact the representative of the marketing authorization holder:
GSK Services Sp. z o. o.
tel. +48 22 576 90 00
Date of last revision of the leaflet:January 2025